Top Markets
Coin of the day
Cotinga Pharmaceuticals Inc. Cotinga Pharmaceuticals Inc.

Cotinga Pharmaceuticals Inc.

COTQF
Rangering i aksjer #42319
Cotinga Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm focused... Cotinga Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative treatments for cancer and other medical conditions currently lacking adequate solutions. Its leading therapeutic asset is COTI-2, an oral small molecule formulated to target the p53 tumor suppressor gene. The company is also progressing COTI-219, another oral small molecule compound, specifically engineered to inhibit mutant forms of KRAS without affecting the normal functions of the KRAS gene. In collaboration with St. Vincent's University Hospital, Cotinga is conducting research to evaluate COTI-2 when combined with eribulin for patients suffering from triple-negative metastatic breast cancer. The company, which was previously known as Critical Outcome Technologies Inc., rebranded to Cotinga Pharmaceuticals Inc. in January 2018. Its corporate base is situated in Toronto, Canada.
Aksjekurs
$0.0001
Sist synkronisert: 2026-07-02
Markedsverdi
$2.20K
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
CA
Handel Cotinga Pharmaceuticals Inc. (COTQF)

Kategori

Inntekter for Cotinga Pharmaceuticals Inc. (COTQF)
Inntekter i 2026 TTM: 0
Ifølge Cotinga Pharmaceuticals Inc. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Cotinga Pharmaceuticals Inc. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$5.27B -
US
$1.95B -
NL
- -
CH
- -
KR
$3.01B -
BE